2. Academic Validation
  3. CT45A1 promotes the metastasis of osteosarcoma cells in vitro and in vivo through β-catenin

CT45A1 promotes the metastasis of osteosarcoma cells in vitro and in vivo through β-catenin

  • Cell Death Dis. 2021 Jun 25;12(7):650. doi: 10.1038/s41419-021-03935-x.
Mingxin Wen 1,  Hui Ren 2,  Shouqiang Zhang 3,  Tao Li 4,  Jiefeng Zhang 5,  Peng Ren 6
Affiliations

Affiliations

  • 1 Department of Anatomy, Shandong University School of Medicine, Jinan, Shandong, PR China.
  • 2 Department of thoracic surgery, Central Hospital of Xinwen Mining Group Company, Xintai, Shandong, PR China.
  • 3 Department of Traumatology, The Second Hospital of Shandong University, Jina, PR China.
  • 4 Trauma department of orthopedics, Shandong University School of Medicine, Jinan, Shandong, PR China.
  • 5 Department of Traumatology, Taian City Central Hospital, Taian, PR China.
  • 6 Trauma department of orthopedics, The Second Hospital of Shandong University, Jina, PR China. renpeng2017@163.com.
PMID: 34172717 DOI: 10.1038/s41419-021-03935-x
Abstract

Increased expression of Cancer/testis antigens (CTAs) is reported in various tumors. However, the unique role of CTAs in tumor genesis has not yet been verified. Here, we first report the functional role of CT45A1 in the carcinogenesis of osteosarcoma. RNA Sequencing and immunohistochemistry confirmed that elevated expression of CT45A1 was detected in osteosarcoma, especially in metastatic tissues of osteosarcoma. Furthermore, osteosarcoma patients with poorer prognosis showed high expression of CT45A1. In cell tests, CT45A1 overexpression was shown to strengthen the proliferation, migration, and invasion abilities of osteosarcoma cells, while silencing CT45A1 markedly elicited the opposite effects in these tests by disrupting the activation of β-catenin. In summary, we identify a novel role of CT45A1 in osteosarcoma. Furthermore, our results suggested that CT45A1 may contribute to the development of osteosarcoma and could be a possible therapeutic target for osteosarcoma patients.

Figures
Products